RAS or RAF mutations may render MM cells resistant to treatment with ERBB1/EGFR1 inhibitors and limit any potential clinical benefit to MM patients with a KRAS/NRAS/BRAF triple wildtype genotype [67]. Here, KRAS is linked to Miyoshi myopathy.